Related Experiment Videos
Simultaneous use of mitomycin-C with Baerveldt implantation
A Azuara-Blanco1, M R Moster, R P Wilson
1Glaucoma Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA.
Background And Objective:
To evaluate the outcome of Baerveldt implantation with adjunctive mitomycin-C in cases of complicated glaucoma.
Patients And Methods:
The authors reviewed the charts of all patients who had undergone Baerveldt implantation with mitomycin-C between January 1993 and March 1995. Success was defined before data collection as an intraocular pressure (IOP) between 5 and 21 mm Hg, with or without medications. The success rate was calculated using the Kaplan-Meier actuarial method.
Results:
Twenty-nine patients were identified. The mean preoperative IOP was 33.6 mm Hg, with an average of 2.0 antiglaucoma medications. The probability of success at 6 and 12 months for patients who received mitomycin-C during Baerveldt implantation was 82.4% and 73.3%, respectively. Choroidal effusion with a flat anterior chamber (10.3%), corneal edema (6.8%), and conjunctival erosion (6.8%) were the most frequent complications.
Conclusion:
In this retrospective series of complicated glaucoma, the implantation of a Baerveldt drainage device with adjunctive mitomycin-C had a satisfactory outcome. The complications encountered and the clinical efficacy were comparable to those of previously reported series in which mitomycin-C was not used.